{"eventGroups":[{"deathsNumAffected":12,"deathsNumAtRisk":57,"description":"Non-myeloablative peripheral blood stem cell transplant (PBSCT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis. Tacrolimus will be stopped at either Day 90 or Day 180 depending on GVHD status.\n\nFludarabine: Days -6 through -2: 30 mg/m\\^2 IV daily\n\nCyclophosphamide: Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily\n\nTotal body irradiation: Day -1: 200 cGy in a single fraction\n\nTacrolimus: Start on Day 5 through either Day 60 or Day 90 depending on cohort assignment. May be continued through Day 180 depending on GVHD status.\n\nMycophenolate mofetil: Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)","id":"EG000","otherNumAffected":35,"otherNumAtRisk":57,"seriousNumAffected":9,"seriousNumAtRisk":57,"title":"PBSCT D90"},{"deathsNumAffected":10,"deathsNumAtRisk":60,"description":"Non-myeloablative peripheral blood stem cell transplant (PBSCT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis. Tacrolimus will be stopped at either Day 60 or Day 180 depending on GVHD status.\n\nFludarabine: Days -6 through -2: 30 mg/m\\^2 IV daily\n\nCyclophosphamide: Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily\n\nTotal body irradiation: Day -1: 200 cGy in a single fraction\n\nTacrolimus: Start on Day 5 through either Day 60 or Day 90 depending on cohort assignment. May be continued through Day 180 depending on GVHD status.\n\nMycophenolate mofetil: Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)","id":"EG001","otherNumAffected":16,"otherNumAtRisk":60,"seriousNumAffected":5,"seriousNumAtRisk":60,"title":"PBSCT D60"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":35,"numAtRisk":57},{"groupId":"EG001","numAffected":16,"numAtRisk":60}],"term":"neutropenic fever"}],"seriousEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":57},{"groupId":"EG001","numAffected":5,"numAtRisk":60}],"term":"Severe cGVHD"}],"timeFrame":"adverse event data were collected for each particpant for at minimum 1 year. Median follow-up of 41 months in the D90 cohort and 27 months in the D60 cohort."}